Novartis Moves Up First Filing For Auto-Inflammatory Drug ACZ885 In Cryopyrin-Associated Syndromes
This article was originally published in The Pink Sheet Daily
Executive Summary
Canakinumab showcases Novartis Institute for Biomedical Research’s novel subpopulaton proof-of-concept model.
You may also be interested in...
Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis
Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan
Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis
Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan
Drug Development Chief Departs Beleaguered Novartis
Trevor Mundel is set to replace James Shannon, Novartis confirms to “The Pink Sheet” DAILY.